COVID‐19 vaccination in patients with multiple sclerosis: what you need to know – a review

Abstract

Abstract Background The appearance of severe acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2) initiated the COVID‐19 pandemic, resulting in millions of confirmed cases and numerous fatalities. In response, rapid vaccine development efforts were launched to mitigate the pandemic's impact. Despite the high efficacy of COVID‐19 vaccines, they are also associated with several common side effects/complications, some of them specific to the multiple sclerosis population. Our goal is to review various types of COVID‐19 vaccines, assessing their efficacy, adverse events, their association with an MS relapse following vaccination, and the influence of disease modifying therapies (DMTs) on vaccines’ efficacy. Methods The review was based on a database search that included PubMed/Medline, Embase, Scopus, and the Web of Science conducted from January 2020 to July 2024 using the following MeSH terms: MS, COVID‐19, COVID‐19 vaccination, vaccine side effects, and vaccine hesitancy. Results Receiving any type of COVID‐19 vaccine is a safer and more reliable approach to building immunity compared to becoming infected with the virus. Complications tend to be mild to moderate, occasionally severe. DMTs could affect the humoral response to the COVID‐19 vaccine. Among all DMTs, a notable reduction in the humoral response has been observed in patients who received anti‐CD20 and sphingosine‐1‐phosphate (S1P) receptor modulator drugs after their COVID‐19 vaccination. Conclusion Despite certain drawbacks, the benefits of the COVID‐19 vaccine significantly outweigh the associated risks, making it a recommended course of action for people with multiple sclerosis (pwMS). However, physicians need to be mindful of potential complications especially in patients undergoing anti CD20 and manage them appropriately.

Keywords

• COVID‐19
• COVID‐19 vaccine
• disease‐modifying therapies
• immune response
• Multiple Sclerosis
• vaccine safety